FY2025 · ended Dec 31, 2025 · Revenue $41.70M, +11.7% YoY · Filed Mar 19, 2026
Biofrontera Inc. (BFRI) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $41.7 million and a net loss of $10.5 million. Free cash flow was -$13.4 million. As of Jun 30, 2026 it held $4.7 million in cash and investments and $2.9 million in total debt.
Revenue (TTM)
$46.17M
+17.8% vs year-ago TTM
Net income (TTM)
$-6.37M
+61.6% vs year-ago TTM
Operating cash flow (TTM)
$-7.93M
+15.6% vs year-ago TTM
Free cash flow (TTM)
$-7.93M
+15.6% vs year-ago TTM
EPS (TTM)
$-0.54
+74.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
11.65M
+31.3% vs prior year
Net cash
$1.77M
as of Jun 30, 2026
Operating margin
-14.2%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BFRI (Nasdaq), BFRIW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Woburn, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1858685
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $41.7M | $37.3M | $34.1M | $28.7M | $24.1M |
| Operating income | -$11.3M | -$17.2M | -$22.7M | -$18.6M | -$25.2M |
| Net income | -$10.5M | -$17.8M | -$20.1M | -$640,000 | -$37.7M |
| Diluted EPS | -$1.04 | -$3.22 | -$13.02 | — | — |
| Operating cash flow | -$13.4M | -$10.3M | -$24.9M | -$16.2M | -$26.7M |
| Free cash flow | -$13.4M | -$10.3M | -$24.9M | — | — |
| Total assets | $28.6M | $22.1M | $27.9M | $50.9M | $53.2M |
| Total liabilities | $18.1M | $17.7M | $23.1M | $27.0M | $41.9M |
| Stockholders' equity | $10.5M | $4.4M | $4.8M | $23.9M | $11.3M |
| Cash and investments | $6.4M | $5.9M | $1.3M | $17.2M | $24.5M |
| Total debt | $1.6M | $824,000 | $5.4M | $1.3M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-K/A | Amended annual report | Jul 22, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2026 | Jun 11, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
All 365 Biofrontera Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.